Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7752W HIGH $21.60
Volume
26.50 K
Value Traded
51.30 K
Short % Float
8.77%
+11.11%Week
-51.52%1 Month
-67.01%3 Month
-76.56%6 Month
-87.8%5 Year
-94.04%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.74 M
EPS (TTM)
-3.67
P/E Ratio
-
Ent. Value
3.12 M
Total Shares
2.11 M
Float Shares
2.04 M
Insiders
2.96%
Institutions
5.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
LEXX Catalyst Timeline
Dated clinical, regulatory and corporate events for Lexaria Bioscience Corp.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Lexaria Bioscience Corp.
317Total events
8Upcoming
73Tier-1 (high impact)
2012 to 2034Coverage
Upcoming catalysts 2
Event history 50
▲Timing GuidancePresentation
Novo announced weight-loss data for patients switching from injected to oral Wegovy
GLP-1 weight-loss/diabetessource ↗
▲Timing GuidancePresentation
Novo announced oral Wegovy patients lost average 4.1% bodyweight over 3 months after switching from injectables
weight-loss/diabetessource ↗
▼Equity OfferingCorporate
Issuance of new Series A and Series B warrants to purchase up to 453,969 shares each
●Equity OfferingCorporate
Issuance of Series A and Series B warrants to purchase up to 453,969 shares each
▲Timing GuidancePresentation
Novo CEO stated oral medications could capture as much as half of global GLP-1 market
GLP-1 weight-loss/diabetessource ↗
▲Full ResultsamycretinClinical Data
PK bioanalysis testing completed in 2026 Animal Study #2 for amycretin
GLP-1source ↗
▲Full ResultsretatrutideClinical Data
PK bioanalysis testing completed in 2026 Animal Study #2 for retatrutide
GLP-1source ↗
▲Full ResultsDehydraTECHClinical Data
PK bioanalysis testing completed in 2026 Animal Study #2
GLP-1 drugssource ↗
▼Equity OfferingCorporate
Registered direct offering of 2,661,600 shares at $1.315 per share, with warrants
▼Equity OfferingCorporate
Registered direct offering of 2,666,667 shares at $1.50 per share for $4.0 million gross proceeds
▼Equity OfferingCorporate
Lexaria announces $2 million registered direct offering of common stock
◆Trial InitiationDehydraTECH-CBDTrial
Phase 1b hypertension study likely to begin in first half of 2025
hypertensionsource ↗
◆Trial InitiationDehydraTECH-GLP-1Trial
Australian-registered Phase 1b DehydraTECH-GLP-1 diabetes and weight-loss study to begin
diabetes and weight losssource ↗
●Timing GuidancePresentation
Injected GLP-1 drugs captured 93% of market in 2025
GLP-1 weight-loss/diabetessource ↗
◆Management ChangeCorporate
CEO transition: Chris Bunka steps down, Richard Christopher appointed as new CEO
▲Interim AnalysisTrial
Positive interim body weight results from first four weeks of dosing in diabetes animal study
diabetessource ↗
▲IND ClearanceDehydraTECH-CBDIND
FDA clearance for Phase 1b hypertension trial with DehydraTECH-CBD
hypertensionsource ↗
▼Equity OfferingCorporate
Registered direct offering of 1,558,443 shares at $2.31 per share for gross proceeds of $3.6 million
▲Full ResultsDehydraTECHClinical Data
Positive final results from human pilot study of DehydraTECH-powered semaglutide vs Rybelsus
GLP-1 drug deliverysource ↗
▼Equity OfferingCorporate
Raised over $8.5 million during 2024 through equity raises and warrant exercises
▲Partnership / LicenseCorporate
Global exclusive license for non-pharmaceutical uses of DehydraTECH-sulforaphane granted to SulfoSyn
▲Patent GrantedIP / Competition
Canadian Patent #2,984,917 granted for stable ready-to-drink beverage compositions
▲Patent GrantedIP / Competition
Canadian Patent #3,111,082 granted for lipophilic active agent infused tobacco leaves
nicotine addictionsource ↗
◆Topline ReadoutClinical Data
Lexaria expects to release NIC-H22-1 results within two weeks
nicotinesource ↗
▲Partnership / LicenseCorporate
Lexaria incorporates Lexaria Nutraceutical Corp. and grants exclusive perpetual license for DehydraTECH in CPG products
▲Full ResultsDehydraTECH-nicotineClinical Data
Human oral nicotine study showing faster absorption and better tolerability vs Zyn and On!
oral nicotinesource ↗
▲Trial InitiationTrial
Early-stage work program into GLP-1 drug categories launched
GLP-1 for weight losssource ↗
▲Runway Guidance UpdateCorporate
Existing resources expected to be sufficient until mid-year 2023
▲Full ResultsDehydraTECH-CBDClinical Data
Animal diabetes study showing blood sugar reduction and kidney function improvement
blood glucose and diabetessource ↗
▼Equity OfferingCorporate
Pricing of $2.0 million public offering of 2,106,000 units at $0.95 per unit
▲Full ResultsDehydraTECH-CBDClinical Data
Final results showing interleukin biomarker reduction
hypertensionsource ↗
▲Full ResultsDehydraTECH-estradiolClinical Data
Rodent study showing enhanced absorption of estradiol and estrone
hormone deliverysource ↗
▲Trial CompletionDehydraTECH-CBDTrial
Diabetes animal model study DIAB-A22-1 completed
diabetessource ↗
▲Full ResultsDehydraTECH-CBDClinical Data
Positive results from DIAB-A22-1 study announced
diabetessource ↗
▲Full ResultsDehydraTECH-CBDClinical Data
8-week rodent study showing triglyceride and body weight reduction
diabetes and weight losssource ↗
▲Full ResultsDehydraTECH-CBDClinical Data
Follow-up results from hypertension study showing catestatin reduction
hypertensionsource ↗
●Quarterly UpdateCorporate
CEO letter to stakeholders summarizing 2022 progress and 2023 outlook
▲First Patient DosedDehydraTECH-CBDTrial
Phase 1(b) FDA-registered study expected to begin in 2023
hypertensionsource ↗
Past FDA Catalysts and PDUFA Decisions
How LEXX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D25 / 100
Pipeline Score
$0M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 83%
Micro Cap(rank 546 of 658)
Percentile Rank
Lexaria Bioscience Corp. faces pipeline headwinds (25/100), with $356M risk-adjusted pipeline value, led by DehydraTECH-CBD alone in Type2diabetes (Phase 1), across $101B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DehydraTECH-CBD alone Small moleculeCompletedNCT06648031 | Type2diabetes | Phase 1 | COMPLETED | 148 | Jul 31, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every LEXX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| liraglutide | diabetes | 2024-07-17 | body weight gain: initial acclimation 10.9%, dehydra TECH liraglutide weight loss -1.58%, dehydra TECH CBD3 weight loss -1.50%; weight loss 5 percent: only in Study arms A, B, C, and ERead More | Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC tRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| BUNKA CHRISTOPHERDirector | Disposition | -100,000 273,543 held | $0.00 | 03/17/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in LEXX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in LEXX for Q2 2026. | ||||
LEXX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How LEXX ranks across every disease it competes in
Competitive Position is a premium feature
See how LEXX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialLEXX News
LEXX▲ +17%on this news
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
Lexaria Bioscience Corp. reports significant growth in the oral GLP-1 market, projected to rise from $5.1 billion in 2026 to $89 billion by 2034. The company’s DehydraTECH technology is being evaluated for its potential in this expanding sector. Novo's recent announcements support the trend towards oral medications, with early data showing positive outcomes for patients switching from injectables.
Read more →LEXX▲ +6.3%on this news
Lexaria Updates Financial Position
Lexaria Bioscience Corp. has announced a strong financial position following a $7.9 million capital raise from an Australian tax refund and institutional financing. CEO Rich Christopher expressed frustration over the stock's performance amid aggressive trading but remains optimistic about the company's future. Lexaria's cash runway is extended through 2027, allowing for continued business development and R&D efforts.
Read more →LEXX▼ -38.6%on this news· ran to -51% by day 3
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria Bioscience Corp. has successfully closed the exercise of certain warrants, generating approximately $5.9 million in gross proceeds. The company issued 453,969 shares at a reduced exercise price and introduced new Series A and Series B warrants. The funds will be utilized for working capital and corporate purposes, supporting Lexaria's innovative drug delivery platform.
Read more →LEXX▼ -33.8%on this news· ran to -72% by day 3shared move
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
Lexaria Bioscience Corp. has announced the immediate exercise of warrants, resulting in approximately $5.9 million in gross proceeds. The exercise involves 453,969 shares at a reduced price of $12.92 per share. The funds will be used for working capital and R&D initiatives. The transaction is expected to close on September 9, 2026.
Read more →LEXX▲ +14.9%on this news· ran to -67% by day 3shared move
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Lexaria Bioscience Corp. will participate in the 28th Annual H.C. Wainwright Global Investment Conference from September 14-16, 2026, in New York City. CEO Richard Christopher will present the company's advancements and be available for one-on-one meetings with investors. The event highlights Lexaria's innovative drug delivery platform, DehydraTECH.
Read more →LEXX▲ +10.6%on this news· ran to +25% by day 3shared move
Lexaria Receives USD$2.6 Million Tax Rebate Payment
Lexaria Bioscience Corp. has announced the receipt of a USD$2.6 million cash rebate from the Australian Tax Office. This rebate, resulting from their compliance with the Australian R&D Tax Incentive Program, will be used to fund future research and development initiatives. The company emphasizes that this funding avoids shareholder dilution and supports their ongoing R&D efforts.
Read more →LEXXDehydraTECH™-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria’s 2026 Animal Study #2
Lexaria Bioscience Corp. announced significant improvements in drug absorption for its DehydraTECH 3.0 formulations of amycretin and retatrutide in a recent animal study. The study demonstrated over double the bioavailability for amycretin and an astonishing 4,552% increase for retatrutide compared to earlier formulations. These results bolster Lexaria's efforts in developing oral delivery systems for next-generation GLP-1 drugs.
Read more →LEXX▲ +32.4%on this news· ran to +88% by day 3
Lexaria Enters a Material Transfer Agreement With PegBio
Lexaria Bioscience Corp. has signed a Material Transfer Agreement with PegBio Co., Ltd to explore the application of its DehydraTECH technology with PegBio's proprietary GLP-1 molecule. This partnership aims to evaluate the pharmacokinetic performance of the molecule in animal studies. Lexaria's CEO expressed optimism about the collaboration, which could enhance the accessibility and effectiveness of PegBio's diabetes-related drugs.
Read more →LEXX▼ -11.9%on this news
Lexaria Announces Effective Date for Reverse Stock Split
Lexaria Bioscience Corp. announced a reverse stock split effective August 3, 2026, to increase its stock price and comply with NASDAQ's minimum bid requirement. The split will consolidate shares on a 1-for-15 basis, reducing the number of shares from approximately 24.8 million to about 1.65 million. The company aims to stabilize its stock amid market challenges and enhance its appeal to investors and business partners.
Read more →LEXXLexaria Updates Business Development
Lexaria Bioscience Corp. reported successful meetings with various pharmaceutical partners at the 2026 BIO International Convention. The company is focusing on advancing existing relationships while exploring new opportunities, particularly in the GLP-1 sector. There is a notable shift towards drug safety and tolerability among industry players. Additionally, interest in Lexaria's DehydraTECH technology is expanding beyond its initial applications.
Read more →LEXXLexaria’s Human Study GLP-1-H26-7 Has Begun Dosing on Schedule
Lexaria Bioscience Corp. has commenced dosing for its Human Pilot Study #7, evaluating its DHT-sema compositions against Novo Nordisk's Wegovy tablets. The study aims to assess safety, tolerability, and pharmacokinetic properties over five weeks. Lexaria is implementing new enhancements in its formulations, including the use of oral tablets for the first time. Results are anticipated to attract interest from the pharmaceutical industry.
Read more →LEXXLexaria’s Animal Study GLP-1-A26-1 Has Begun Dosing on Schedule
Lexaria Bioscience Corp. has commenced dosing for its Animal Study #1 (GLP-1-A26-1) on schedule, focusing on enhancing drug formulations using DehydraTECH technology. The study aims to evaluate new formulations against existing standards and has already led to the filing of three new patent applications. Results are expected by early September 2026.
Read more →LEXXGLP-1 ‘Arms Race’ Intensifies as the Addressable Markets Continue to Expand
Lexaria Bioscience Corp. reports a surge in GLP-1 drug prescriptions, particularly for weight loss, with over three million Wegovy prescriptions filled since January 2026. The company highlights the expanding indications for GLP-1 drugs, including obesity-related conditions. Additionally, Lexaria's DehydraTECH technology aims to improve drug delivery and reduce side effects, positioning the company favorably in a competitive market.
Read more →LEXXLexaria’s Animal Study Examining Next-Generation GLP-1 drugs is Underway
Lexaria Bioscience Corp. has completed dosing in its 2026 Animal Study evaluating the compatibility of its DehydraTECH technology with next-generation GLP-1 drugs, retatrutide and amycretin. The study aims to explore improved oral dosing formulations and assess pharmacokinetic performance. If successful, it could expand the applicability of DehydraTECH and establish new intellectual property claims.
Read more →LEXXLexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
Lexaria Bioscience Corp. is set to attend the BIO International Convention in San Diego from June 22-25, 2026. The company's participation follows a successful attendance at last year's event, which catalyzed its business development program. Lexaria is experiencing heightened interest in its DehydraTECH platform, leading to numerous collaborative discussions with various industry players.
Read more →LEXXLexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
Lexaria Bioscience Corp. has received ethics approval for its Human Pilot Study #7, which will evaluate its DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets. The study aims to assess safety, tolerability, and pharmacokinetic performance over five weeks. Lexaria's advancements in oral drug delivery could lead to significant commercial opportunities in the pharmaceutical industry.
Read more →LEXXLexaria Bioscience Releases Second Episode of Investor Video Series
Lexaria Bioscience Corp. has released the second episode of its investor video series featuring CEO Rich Christopher. The episode discusses the extension of a Material Transfer Agreement with a pharmaceutical partner until the end of 2026 and outlines the company's research priorities for GLP-1. Lexaria aims to enhance its clinical evidence and expand partnerships within the drug delivery sector.
Read more →LEXXLexaria Updates Progress on Human Study #7
Lexaria Bioscience Corp. has provided an update on its Human Pilot Study #7, which will evaluate two new oral DHT-sema compositions against Novo Nordisk's Wegovy tablets. The company has submitted requests for ethics approval and completed laboratory work for the study. The five-week study aims to assess safety, tolerability, and pharmacokinetic properties, with dosing expected to begin in mid-June.
Read more →LEXX▲ +7.9%on this newsshared move
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
Lexaria Bioscience Corp. has launched an investor video series called 'Reformulated: Into the Mainstream' to enhance communication with shareholders. The inaugural episode features CEO Rich Christopher discussing the DehydraTECH platform and its relevance to the GLP-1 market, which saw $75 billion in revenue in 2025. The series aims to provide ongoing insights into the company's strategies and developments.
Read more →LEXX▼ -21.9%on this newsshared move
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
Lexaria Bioscience Corp. has successfully extended its Material Transfer Agreement with a pharmaceutical company until December 31, 2026. This extension allows for further evaluation of Lexaria's DehydraTECH technology in pre-clinical settings, particularly related to GLP-1. The company has made significant progress in its GLP-1 development program, with results expected in the latter half of 2026.
Read more →About Lexaria Bioscience Corp.
Headquarters100 - 740 MCCURDY ROAD, KELOWNA, A1, V1X 2P7
BIOPHARMAWATCH ELITE PLUS
Trade the next LEXX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime